Coronavirus Research Hub FAQ's

What’s New

We are offering a collection of clinical, bio-medical and life sciences research resources and solutions to the community for free, for Coronavirus research through 28th of October 2020. These services may be used by academic, government, not-for-profit and commercial researchers.

We will initially give priority access to researchers working on vaccine, drug, and clinical research while we are working hard to increase the capacity and capabilities of the platform for further use cases.

The Elsevier Coronavirus Research Hub will include access to ClinicalKey, Embase, SSRN, Mendeley Data, the Science Direct Covid-19 collection, Elsevier Text Mining (ETM), Mendeley and the Pure Covid-19 Portal. We plan to bring Reaxys and Veridata EDC online shortly.


Our License Explained

Once you receive a confirmation email, you will be granted a free license to use the resources and solutions presented on the Elsevier Coronavirus Research Hub. The full license is here.

You may use the resources and solutions exclusively for the purpose of conducting Coronavirus research, in the area(s) you specified during your application.

You must acknowledge the "Elsevier Coronavirus Research Hub" as a source in any publications.

The license is valid until 28th October 2020.

This is an individual license for your research only. You must keep your password secure, and you may not share it with others. We reserve the right to inactivate your account if you are not conducting legitimate Coronavirus research.

Elsevier makes no warranties regarding the suitability or availability of these resources or solutions.


Multiple Accounts

You may already be registered for some of the Elsevier resources and services through your institution’s license. The functionality may differ - for example the Coronavirus Research Hub does not allow you to access APIs or to bulk download content. In this case, please log out and then log in again through your institutional access.


The Application Process

Please use your academic, institutional, or corporate email account for registration. There may be delays or further accreditation necessary if you use a non-institutional email account.

If you register without an institutional email account, we may ask you for endorsement by a department head listed on the institution's public website through her/his institutional email account.

Elsevier Text Mining and Veridata EDC require a manual setup, which you can request after your completed application.

Veridata EDC requires a data processing agreement to be GCP, GDPR and HIPAA compliant. You can test the system and set up your study immediately but we should sign a data processing agreement before you begin to collect patient data.

The application process may take up to 72 hours to complete.


Why do you need my institutional email?

Some of our solutions have limitations on the number of users they can support. We want to ensure that the resources as a whole are reserved for bona fide researchers and that systems have enough capacity for them to productively conduct their work. While we recognize that there are many excellent researchers outside of traditional academic, government and life science institutions, accrediting these researchers is much more difficult.


No Marketing

We will only use your email for notifications about your work on the Coronavirus Research Hub. We will not send you any marketing materials.


Concurrent User Constraints

Embase and Elsevier Text Mining only support limited concurrent users. These established research solutions were developed for a much smaller audience in life-sciences research on vaccines and drugs. We are working hard to increase capacity.


Our Partners

The COVID-19 Research Database is a collection of data sets made freely available to public health and policy researchers to extract insights for combatting the pandemic.

Ready to take the next step?
The Elsevier Coronavirus Research Hub is waiting for you.

Get access

Your feedback

Your feedback

Please give us your feedback on the Coronavirus Research Hub